The home-collected vaginal samples can be shipped to CLIA-certified labs for testing on the Roche Cobas system.

Last week, readers were most interested in a story about Castle Biosciences' buy of Previse and its plans to expand its gastrointestinal diagnostic test offerings.

The agreement enables rapid diagnostic test manufacturing in the Africa region and will initially focus on HIV testing.

The firm filed for Chapter 11 protection on Thursday and is seeking to sell its assets after facing turmoil in recent years.

The money will support the development of the firm's PidPort system for storage, viewing, sharing, and analysis of digital images of pathology slides.

April's clearances included respiratory disease assays, a Gram-negative infection test, and assays to aid the diagnosis and monitoring of thyroid disease.

The company has received a commitment of up to $12.5 million in a multi-draw DIP financing facility to provide funding during the proceeding.

NEW YORK — Exagen, a developer of autoimmune testing technologies, said on Thursday it expects to raise around $17.6 million through a public offering of its common stock.

The firm has been engaging with payors and insurance plan administrators following the release of results from its study on the use of the firm's PreTRM Test.

The firm reported that its total revenues jumped 9 percent in Q2, but it lowered the low end of its EPS guidance to account for the uncertainty of tariffs and other trade barriers.